

<i>Short Name</i>	<i>Comments</i>	<i>Type</i>	<i>Investigator</i>	<i>Contact</i>
<b><i>Disease site specific</i></b>				
<b><i>Staging, DCIS, Stage 0, Stage 1, Stage 2</i></b>				
Alliance A011104	Preoperative Breast MRI on Surgical Outcomes, Cost, and Quality of Life. Stage I-II; ER Neg/PR Neg & HER-2 Neg Breast OR ER Neg/PR Neg & HER-2 Positive Tumors  <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
CCTG Ma.39	A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<b><i>Surgical/ Radiation</i></b>				
<b>None</b>				
<b><i>Neoadjuvant</i></b>				
NSABP B-51	Any ER/PR/HER2; NEOADJUVANT/ Staging: T1-3; Treatment: RT for Patients Who Convert to Path Negative Nodes After Neoadjuvant Chemo and Surgery  <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	<a href="#">CRCWM (616) 391-1230 www.crcwm.org</a>
A011202	A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy  <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	<a href="#">CRCWM (616) 391-1230 www.crcwm.org</a>
MA39	Tailor RT: A randomized trial of regional radiotherapy in biomarker low risk node positive breast cancer	Treatment	<a href="#">CRCWM Physician Investigators</a>	<a href="#">CRCWM (616) 391-1230 www.crcwm.org</a>

### Adjuvant Trials

PVB VS PNB	<b>Paravertebral Block Versus Pectoral Nerve Block for Analgesia Following Mastectomy</b>	Treatment	<a href="#">Melnik, Marianne</a>	Marianne Morrissey <a href="mailto:cancer.research@spectrumhealth.org">cancer.research@spectrumhealth.org</a> (616) 486-8500
<i>The purpose of this study is to compare two standard methods of pain control management for patients undergoing breast surgery.</i>				
NRG BR003	<b>TRIPLE NEGATIVE; Adjuvant; HIGH RISK NODE(-)or NODE(+)</b> / Invasive; A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
NSABP B-55	<b>TRIPLE NEGATIVE: BRCA+; Adjuvant; High Risk/ Treatment: <u>Olaparib vs Placebo</u></b>  <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
A011502	<b>A Randomized Phase III Double-Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for <b>Node-Positive, HER2 Negative Breast Cancer</b>; the <u>Aspirin for Breast Cancer Study (ABC Study)</u></b>  <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
NRG CC004	<b>Phase II Double Blind Dose Finding Trial of Bupropion Versus Placedbo for Sexual Desire in Women with Breast or Gynecologic Cancer</b>  <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>

S1418	<b>TRIPLE NEGATIVE: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Caqncer with &gt;/=1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy</b> <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EA1131	<b>TRIPLE NEGATIVE; Adjuvant; BASAL-LIKE Breast Cancer; Phase III Post-Operative; Platinum Based Chemotherapy vs Observation in Patients with Residual following Neoadjuvant Chemotherapy</b> <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
SWOG S1207	<b>ER/PR(+) &amp; HER2-;Adjuvant; Stage I-III; Oncotype Testing Required for Patients with &lt;4 Positive Lymph Nodes. Treatment: Endocrine Therapy + <u>Everolimus/Placebo</u></b> <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
CTSU E1Z11	<b>BREAST - ER/PR+; Any HER2; Adjuvant / Stage I - III Adenocarcinoma. Treatment: Anastrozole. <u>Only the Asian and Native Hawaiian/Pacific Islanders cohorts remain open to accrual</u></b> <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<b>Stage IIIC, Locally advanced and Stage IV</b>				
CTSU E2112	<b>ER/PR+; Her2-; Stage IIIC or IV; Treatment: Endocrine Therapy plus <u>Entinostat/Placebo</u></b> <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>

ACCRU RU011201I	Any ER/PR; <b>HER2-</b> ; Stage IIIC or IV; Not Amenable to Local Therapy. Treatment: <u>Eribulin</u> vs Paclitaxel  <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="#">www.crcwm.org</a>
WF97116	A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment  <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="#">www.crcwm.org</a>
S1416	Phase II Rancomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in <b>Metastatic Triple-Negative</b> Breast Cancer and/or BRCA Mutation-Associated Breast Cancer  <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="#">www.crcwm.org</a>
S1703	Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Postive Breast Cancer	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="#">www.crcwm.org</a>
<b>HER2+</b>				
AFT-38 "Patina"	A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2 - Positive Metastatic Breast Cancer  <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="#">www.crcwm.org</a>
S1501	Prospect Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic Her-2+ Breast Cancer, Phase III  <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="#">www.crcwm.org</a>

**BRCA +***None***Any ER/PR/HER2**

SCRI BRE 203

**Any ER/PR/HER2; METASTATIC/ Stage IV** Must be AR+ and fit into one of these: A. ER-/PR-/Her2-/AR+ with 1-3 previous treatment for metastatic disease. B. Postmenopausal ER+ and/or PR+/AR + refractory MCB with progression after 1-3 hormonal treatments.

Treatment: *Orteronel*[For More Information](#)

Treatment

[CRCWM](#)[Physician](#)[Investigators](#)

CRCWM

(616) 391-1230

[www.crcwm.org](#)**Breast only symptom management**

S1501

**Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic Her-2+ Breast Cancer, Phase III**

[For More Information](#)

Treatment

[CRCWM](#)[Physician](#)[Investigators](#)

CRCWM

(616) 391-1230

[www.crcwm.org](#)**Protocols that are NOT disease site specific****Treatment**Alexion  
ALXN6000-ONC-102

**Alexion Protocol ALXN6000-ONC-102: A Multicenter, Dose-Escalation, Phase 1 Study of Samalizumab (ALXN6000) to Evaluate the Pharmacokinetics, Safety, and Tolerability in Patients with Advanced Cancer**

Treatment

[START](#)[Midwest](#)[Investigators](#)

START Midwest

(616) 954-5554

**A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity**

Treatment

[START](#)[Midwest](#)[Investigators](#)

START Midwest

(616) 954-5554

**A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of intravenously Administered APG-1252 in Patients with Small Cell Lung Cancer (SCLC) and Other Solid Tumors**

Treatment

[START](#)[Midwest](#)[Investigators](#)

START Midwest

(616) 954-5554

	<b>A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-115 in Patients with Advanced Solid Tumors or Lymphomas</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
	<b>A Phase 1a/2a Cohort Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID100, an Anti-Human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Linked to the Maytansinoid DM1, in Patients with Advanced or Metastatic Solid Tumors of Epithelial Origin</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>ALEXO AT148001</b>	<b>Alexo Protocol AT148001: A Phase 1, Dose Escalation Study of ALX148 in Patients with Advanced Solid Tumors and Lymphoma</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>BGB-290</b>	<b>A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
	<b>A First-in-Human Phase 1, Dose Escalation, Safety and Pharmacokinetic Study of PF-06647020 in Adult Patients with Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>SCI-CD47-001</b>	<b>First-in-Human Phase I Dose Escalation Trial of HU5F9-G4 in Patients with Advanced Solid Malignancies</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>MK-4280-001</b>	<b>A Phase Ib/II Study to Evaluate the Safety and Tolerability of Preladenant as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Malignancies</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554

<b>LZM009-001</b>	<b>A First-in-Human, Multicenter, Open-label, Phase 1 Dose Escalation Study of LZM009 in Subjects with Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>ASN002</b>	<b>A Phase I/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ASN002 in Relapsed/Refractory Lymphoma and Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>20150195 AMG 820</b>	<b>A Phase Ib/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination with Pembrolizumab in Select Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>R3767-ONC-1613</b>	<b>A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1-mAb) in Patients with Advanced Malignancies</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>CP-MGA012-01</b>	<b>A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>MK-4820</b>	<b>A Phase 1 Trial of MK-4820 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>ASN003-101</b>	<b>A Phase I, Open-Label, Dose-Finding and Cohort Expansion Study of ASN003 in Subjects with Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554

<b>MK-8353-013</b>	<b>A Phase 1b Study to Evaluate the Safety and Tolerability of MK-8353 in Combination with Pembrolizumab in Patients with Advanced Malignancies</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>5F9004</b>	<b>A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>CP-MGA012-01</b>	<b>A Phase 1 Study of the Safety, tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>CVM-001</b>	<b>A Phase I Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients with Advanced Cancer</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>APX_CLN_0011</b>	<b>A Phase 1 Study of APX3330 in Patients with Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>CPI-1205-202</b>	<b>A Phase 1 Study of CPI-1205 with Ipilimumab or Pembrolizumab in Patients with Advanced Solid Tumors Followed by a Phase 2 Basket Study of CPI-1205 with Ipilimumab or Pembrolizumab in Selected Tumor Types Previously Treated with PD-1 or PD-L1 Inhibitors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>NRG CC003</b>	<b>Randomized Phase II/III Trial of Prophylactice Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer</b>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			



NRG CC001	<b>A Randomized Phase III Trial of Memantine and Whole Brain Radiotherapy With or Without Hippocampal Avoidance in Patients with Brain Metastases</b> <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
A071401	<b>Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations</b>  <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<b><i>Molecular Profiling</i></b>				
QOL Multisite EAQ-152	<b>EAQ-152 - (COMET MATCH) - A randomized Study of Pre-disclosure Genetic Education v Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling</b>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EAY131 - MATCH	<b>MOLECULAR ANALYSIS / ADVANCED REFRACTORY SOLID TUMORS OR LYMPHOMAS; Targeted Therapy Directed by Genetic Testing –</b> See sub-protocols below  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EAY131	<b><i>Dasatinib</i> in Patients with Tumors with DDR2 Mutations</b>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>

EAY131 - A	<b>Solid Tumors (Other than SC &amp; NSCLC) or Lymphomas; <u>Afatinib</u> in Patients that have Activating Mutations of EGFR and Have Progressed After Standard Treatment</b>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="#">www.crcwm.org</a>
EAY131 - B	<b>Tumors with HER2 Activating Mutations; Treatment: <u>Afatinib</u></b>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="#">www.crcwm.org</a>
EAY131 - C1	<b><u>Crizotinib</u> in Patients with Tumors with MET Amplification</b>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="#">www.crcwm.org</a>
EAY131 - C2	<b><u>Crizotinib</u> in Patients with Tumors with MET Exon 14 Deletion</b>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="#">www.crcwm.org</a>
EAY131 - E	<b>Tumors Having EGFR T790M Mutations (Except NSCLC) or Rare Activating Mutations of EGFR; Treatment: <u>AZD9291</u></b>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="#">www.crcwm.org</a>
EAY131 - F	<b>Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Translocations; Treatment: <u>Crizotinib</u></b>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="#">www.crcwm.org</a>

EAY131 - G	<b>ROS1 Translocations (Other Than Patients with NSCLC); Treatment: <u>Crizotinib</u></b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<a href="#">For More Information</a>				
EAY131 - H	<b>Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer); Treatment: <u>Dabrafenib</u> and <u>Trametinib</u></b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<a href="#">For More Information</a>				
EAY131 - J	<b><u>Trametinib</u> and <u>Pertuzumab</u> (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<a href="#">For More Information</a>				
EAY131 - L	<b>Phase II Study of MLN0128 (<u>TAK-228</u>) in Patients with Tumors with mTOR Mutations</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<a href="#">For More Information</a>				
EAY131 - M	<b>Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<a href="#">For More Information</a>				
EAY131 - R	<b>BRAF Fusions, or Non-V600E, Non-V600K BRAF Mutations; Treatment: <u>Trametinib</u></b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<a href="#">For More Information</a>				

EAY131 - S1	<b><u>Trametinib</u></b> in Patients with Tumors with NF1 Mutations	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - S2	<b><u>Trametinib</u></b> in Patients with Tumors with GNAQ or GNA 11 Mutations	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - T	<b>Tumors (except basal cell skin carcinoma) with Smoothed (SMO) or Patched 1 (PTCH1) Mutations; Treatment: <u>GDC-0449</u> (<u>vismodegib</u>)</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - V	<b>Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) Treatment: <u>Sunitinib</u></b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - W	<b>Phase II Study of <u>AZD4547</u> in Patients with Tumors with Aberrations in the FGFR Pathway</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - X	<b><u>Dasatinib</u></b> in Patients with Tumors with DDR2 Mutations	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			

EAY131 - Y	<b><u>AZD5363</u></b> in Patients with Tumors with AKT Mutations	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - Z1A	<b><u>Binimetinib</u></b> in Patients with Tumors (Other than Melanoma) with NRAS Mutations	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - Z1B	<b>MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - Z1D	<b><u>Nivolumab</u></b> in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - Z1E	<b>Testing <u>LOXO-101</u> as Potentially Targeted Treatment in Cancers with NTRK Genetic Changes</b>		<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - Z1I	<b>Testing <u>AZD1775</u> as a Possible Treatment in People who Have Cancer with BRCA Mutations</b>		<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			

ASCO TAPUR	<b>Targeted Agent and Profiling Utilization Registry Study. <u>All drugs provided.</u></b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
<b>Biorepository</b>				
NCI PDM 9846	<b>Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)</b>	Biobanking	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
SHARE	<b>The Spectrum Health Universal Biorepository Provides a Robust, Diverse Offering of High, Quality Research and Potential Diagnostic Samples Associated with Relevant De-identified Clinical Data to Investigators</b>	Biobanking	Cottingham, Sandra	Spectrum Health Biorepository <a href="mailto:david.chesla@spectrumhealth.org">david.chesla@spectrumhealth.org</a> (616) 267-2629
	<i>This study will collect high-quality biologic specimens including tumor/diseased tissue, matched normal tissue, bodily fluids, and correlating health information from patients with the diagnosis of neoplasm or other conditions and related data for use in laboratory research.</i>			
<b>Assessment/ Education</b>				
URCC 13059 GAP-70	<b>Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy for Advanced Cancer: Reducing Chemotherapy Toxicity in Older Adults</b>	Other	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			

---

**Symptom Management**


---

<b>S1415CD</b>	<b>A Pragmatic Trial To Evaluate a Guideline Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)</b>	Symptom Management	<a href="#">CRCWM</a> <a href="#">Physician</a> <a href="#">Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<a href="#">For More Information</a>				
<b>URCC 04040 YOCAS</b>	<b>A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors</b>	Symptom Management	<a href="#">CRCWM</a> <a href="#">Physician</a> <a href="#">Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<a href="#">For More Information</a>				
<b>URCC 16070</b>	<b>Treatment of Refractory Nausea</b>	Symptom Management	<a href="#">CRCWM</a> <a href="#">Physician</a> <a href="#">Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
<a href="#">For More Information</a>				